Department of Pharmaceutics, ISF College of Pharmacy, Moga, Punjab 142001, India.
Curr Pharm Des. 2024;30(15):1133-1135. doi: 10.2174/0113816128298080240328053845.
CRISPR and gene editing technologies have emerged as transformative tools in medicine, offering unprecedented precision in targeting genetic disorders and revolutionizing drug development. This review explores the multifaceted impact of CRISPR across various medical domains, from hereditary diseases to infectious diseases and cancer. The potential of CRISPR in personalized medicine, therapeutic innovation, and pandemic prevention is highlighted, along with its role in reshaping traditional drug development processes. However, alongside its promise, ethical considerations loom large, particularly regarding germline editing and equitable access to treatments. The commercialization of CRISPR poses further challenges, raising questions about affordability and healthcare equity. Collaboration among scientists, policymakers, and the public is emphasized to navigate the ethical and societal implications of CRISPR responsibly. As the field advances, it is essential to ensure that the benefits of CRISPR are realized while addressing potential risks and maintaining a commitment to the well-being of future generations.
CRISPR 和基因编辑技术已经成为医学领域的变革性工具，在靶向遗传疾病方面提供了前所未有的精准度，并彻底改变了药物研发。本文探讨了 CRISPR 在多个医学领域的多方面影响，从遗传性疾病到传染病和癌症。突出了 CRISPR 在个性化医疗、治疗创新和大流行病预防方面的潜力，以及它在重塑传统药物开发过程中的作用。然而，除了其承诺之外，还存在着巨大的伦理考虑因素，特别是涉及生殖系编辑和公平获得治疗的问题。CRISPR 的商业化带来了进一步的挑战，引发了关于可负担性和医疗保健公平性的问题。强调了科学家、政策制定者和公众之间的合作，以负责任地应对 CRISPR 的伦理和社会影响。随着该领域的发展，必须确保在解决潜在风险的同时实现 CRISPR 的益处，并承诺关注子孙后代的福祉。
